Developers of a key mRNA delivery tech, seeking a piece of Moderna's Covid riches, sue for patent infringement
The lawsuit that Moderna has been dreading finally got to it.
Arbutus and Genevant have sued the big biotech for infringing on their patent on a lipid nanoparticle platform that they say was crucial to the delivery of Moderna’s widely-used Covid-19 vaccine.
And they want a cut of its multibillion riches.
Among other things, the two companies are seeking:
An award of damages sufficient to compensate Arbutus and Genevant for Moderna’s infringement under 35 U.S.C. § 284, in no event less than a reasonable royalty on all infringing sales or other dispositions of Accused Product.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,600+ biopharma pros reading Endpoints daily — and it's free.